Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
McKesson
Cerilliant
Federal Trade Commission
Citi
Covington
Argus Health
QuintilesIMS
Daiichi Sankyo

Generated: January 22, 2018

DrugPatentWatch Database Preview

FLOVENT DISKUS 50 Drug Profile

« Back to Dashboard

When do Flovent Diskus 50 patents expire, and what generic alternatives are available?

Flovent Diskus 50 is a drug marketed by Glaxo Grp Ltd and is included in one NDA. There is one patent protecting this drug.

This drug has seventy-eight patent family members in forty-one countries.

The generic ingredient in FLOVENT DISKUS 50 is fluticasone propionate. There are twenty-six drug master file entries for this compound. Eighty-two suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
Summary for FLOVENT DISKUS 50
Drug patent expirations by year for FLOVENT DISKUS 50
Pharmacology for FLOVENT DISKUS 50

US Patents and Regulatory Information for FLOVENT DISKUS 50

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for FLOVENT DISKUS 50

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Glaxo Grp Ltd FLOVENT DISKUS 50 fluticasone propionate POWDER;INHALATION 020833-001 Sep 29, 2000 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for FLOVENT DISKUS 50

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,389,775 Inhalation device ➤ Subscribe
2,006,107,948 ➤ Subscribe
6,536,427 Inhalation device ➤ Subscribe
6,032,666 Inhalation device ➤ Subscribe
7,225,808 Inhalation device ➤ Subscribe
6,378,519 Inhalation device ➤ Subscribe
2,007,107,724 ➤ Subscribe
5,590,645 Inhalation device ➤ Subscribe
5,860,419 Inhalation device ➤ Subscribe
6,792,945 Inhalation device ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for FLOVENT DISKUS 50

Supplementary Protection Certificates for FLOVENT DISKUS 50

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
269 Luxembourg ➤ Subscribe PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
C0067 France ➤ Subscribe PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
C0014 France ➤ Subscribe PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
C/GB08/026 United Kingdom ➤ Subscribe PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080111; UK EU/1/07/434/002 20080111; UK EU/1/07/434/003 20080111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Accenture
Colorcon
McKinsey
Chubb
AstraZeneca
Daiichi Sankyo
Express Scripts
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot